Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The US Patent and Trademark Office (USPTO) has issued Momenta Pharmaceuticals a patent that covers claims to methods of analysing and processing enoxaparin by analysing chain sequence information.
Subscribe to our email newsletter
Enoxaparin, a low molecular weight heparin (LMWH), is an anticoagulant that helps to prevent thrombosis.
The patent entitled, "Evaluating Mixtures of Low Molecular Weight Heparins By Chain Profiles or Chain Mapping," adds to Momenta’s intellectual property estate related to the characterisation of enoxaparin.
Momenta Pharma president and CEO Craig Wheeler said that they believe this patent strengthens their portfolio of patents and pending applications that provide intellectual property protection around enoxaparin sodium injection USP, also known as generic Lovenox.
Enoxaparin sodium injection USP is marketed by Momenta’s collaboration partner, Sandoz, a division of Novartis.